Pharma BD Deal Intelligence

Chong Kun Dang Pharmaceutical Corporation / Kiora Pharmaceuticals, Inc.

2026 · Licensing/Option · Complete

Effective August 20, 2026, Kiora Pharmaceuticals entered into an Exclusive License and Development Agreement with Chong Kun Dang Pharmaceutical Corporation covering KIO-301, Kiora's molecular photoswitch product candidate. Kiora granted CKD an exclusive, sublicensable license to develop, manufacture, commercialize and seek regulatory approval for the product in South Korea for retinitis pigmentosa and other ophthalmic diseases. Kiora receives a $1 million upfront payment and is eligible for development and regulatory milestone payments plus royalties on future South Korean sales; the aggregate milestone value was not disclosed. Kiora expects CKD to coordinate with its other regional partners, Laboratoires Thea and Senju Pharmaceutical, on a single global Phase 3 trial of KIO-301 in retinitis pigmentosa. NOTE: ingested at pending_review pending enrichment.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2031 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2026 deals